Based on the above observation, we determined the expression of TS in biopsy specimens from 24 patients with pathologically confirmed NSCLC harbouring EGFR‐sensitive mutations, such as EGFR exon 19 deletion (19DEL) or exon 21 mutation (L858R), was examined. This evidence concerns the gene EGFR and non-small cell lung carcinoma.